Commentary on "Phosphodiesterase type 5 inhibitors do not prevent curvature progression but shorten pain duration in the active phase of Peyronie's disease: a retrospective cohort study"

Celeste Manfredi^{1

2}, Eugenio Bologna^{3

4}, Leslie Claire Licari^{3

4}

Affiliations

¹ Unit of Urology, Department of Woman, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Naples, 80131, Italy. manfredi.celeste@gmail.com.
² Department of Urology, Rush University Medical Center, 60612, Chicago, IL, USA. manfredi.celeste@gmail.com.
³ Department of Urology, Rush University Medical Center, 60612, Chicago, IL, USA.
⁴ Unit of Urology, Department of Maternal-Child and Urological Sciences, "Sapienza" University of Rome, Policlinico Umberto I Hospital, 00185, Rome, Italy.

Celeste Manfredi et al. Int J Impot Res. 2024 Apr.

. 2024 Apr;36(2):166-167.

doi: 10.1038/s41443-023-00811-4. Epub 2023 Dec 18.

Celeste Manfredi^{1

2}, Eugenio Bologna^{3

4}, Leslie Claire Licari^{3

4}

¹ Unit of Urology, Department of Woman, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Naples, 80131, Italy. manfredi.celeste@gmail.com.
² Department of Urology, Rush University Medical Center, 60612, Chicago, IL, USA. manfredi.celeste@gmail.com.
³ Department of Urology, Rush University Medical Center, 60612, Chicago, IL, USA.
⁴ Unit of Urology, Department of Maternal-Child and Urological Sciences, "Sapienza" University of Rome, Policlinico Umberto I Hospital, 00185, Rome, Italy.

No abstract available

References

1. Durukan E, Kraglund T, Rashid SA, Thorkilgaard T, Skjødt Jensen CF, Fode M. Phosphodiesterase type 5 inhibitors do not prevent curvature progression but shorten pain duration in the active phase of Peyronie’s disease: a retrospective cohort study. Int J Impot Res. 2023. https://doi.org/10.21203/rs.3.rs-3170469/v1 .
1. Salonia A, Bettocchi C, Capogrosso P, Carvalho J, Corona G, Hatzichristodoulou G, et al. EAU Guidelines on sexual and reproductive health. Edn presented at the EAU annual congress Milan 2023. Available from: https://uroweb.org/guideline/sexual-and-reproductive-health/#10 . Last accessed: 28 Nov 2023.
1. Gonzalez-Cadavid NF, Rajfer J. Laboratory forum: experimental models of Peyronie’s disease. Implications for new therapies. J Sex Med. 2009;6:303–13. - DOI - PubMed
1. Gong W, Yan M, Chen J, Chaugai S, Chen C, Wang D. Chronic inhibition of cyclic guanosine monophosphate-specific phosphodiesterase 5 prevented cardiac fibrosis through inhibition of transforming growth factor β-induced Smad signaling. Front Med. 2014;8:445–55. - DOI - PubMed
1. Ilg MM, Stafford SJ, Mateus M, Bustin SA, Carpenter MJ, Muneer A, et al. Phosphodiesterase type 5 inhibitors and selective estrogen receptor modulators can prevent but not reverse myofibroblast transformation in Peyronie’s disease. J Sex Med. 2020;17:1848–64. - DOI - PubMed